Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BICO Group ABCLLKF +1.84%61 Debt-to-Equity is 0.43 as of Mar. 2026, which is 65% above its 10-year median of 0.26. GuruFocus rates CLLKF with a GF Score™ of 61/100 and a GF Value™ of $3.68 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 704 Medical Devices & Instruments companies, BICO Group AB ranks worse than 65.63% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BICO Group AB's Debt-to-Equity or its related term are showing as below:
CLLKF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.26 Max: 1.05
Current: 0.43
During the past 10 years, the highest Debt-to-Equity Ratio of BICO Group AB was 1.05. The lowest was 0.00. And the median was 0.26.
CLLKF's Debt-to-Equity is ranked worse than 65.63% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CLLKF: 0.43
BICO Group AB (OTCPK:CLLKF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BICO Group AB Debt-to-Equity Related Terms
BICO Group AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BICO Group AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, BICO Group AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BICO Group AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BICO Group AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BICO Group AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BICO Group AB (CLLKF) has a Debt-to-Equity of 0.43 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BICO Group AB and its competitors. This is 65% above median its historical median of 0.26. According to the industry distribution chart, BICO Group AB ranks #462 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 65.6%.
Is BICO Group AB's Debt-to-Equity too high?
BICO Group AB's current Debt-to-Equity of 0.43 is 65% above median its 10-year median of 0.26. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. BICO Group AB's value of 0.43 is 87% above this industry median. Based on the distribution chart, BICO Group AB ranks #462 out of 704 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BICO Group AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BICO Group AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BICO Group AB ranks #462 out of 704 companies for Debt-to-Equity. This places BICO Group AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. BICO Group AB's value of 0.43 is 87% above this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 0.23, BICO Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BICO Group AB's current Debt-to-Equity of 0.43 is 87% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BICO Group AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BICO Group AB's current Debt-to-Equity is 0.43, which is 65% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BICO Group AB stock overvalued right now?
Based on GuruFocus' analysis, BICO Group AB (CLLKF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.68, compared to a current price of $1.55 — trading 57.9% below its estimated fair value. The current Debt-to-Equity is 0.43, which is 65% above median its 10-year median of 0.26 and 87% above the Medical Devices & Instruments industry median of 0.23. BICO Group AB's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BICO Group AB (CLLKF), the current Debt-to-Equity is 0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BICO Group AB (CLLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BICO Group AB stock appears to be undervalued.
The current stock price of $1.55 is trading 57.9% below its estimated GF Value™ of $3.68.
GuruFocus considers BICO Group AB to be Possible Value Trap.
Key valuation signals for CLLKF:
Debt-to-Equity: 0.43 (65% above median its 10-year median of 0.26)
GF Value™: $3.68 vs. price of $1.55 (57.9% below fair value)
Industry Position: 87% above the Medical Devices & Instruments median (#462 of 704)
No single metric tells the full story. See the CLLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BICO Group AB provides hardware, laboratory automation software, and products to automate and increase efficiency in workflows for pharma and biotech companies. Its portfolio includes automated workstations, lab automation software, microscopes and live-cell imaging, 3D cell culture and bioprinting, single-cell dispensing, liquid handling, mixing technologies, and consumables. The Group operates through two segments: Life Science Solutions, the maximum revenue generator, including CYTENA, DISPENDIX, Discover Echo, QInstruments, SCIENION, Cellenion, CELLINK, and BioMatrix, and Lab Automation, consisting of Biosero, which provides the Green Button Go Suite software and automation integration services.
61GF Score
Get the complete analysis for CLLKF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLLKF has been successfully added to your 
